Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25319660 | 0.87 | MAP3K5 (0.39) | MAP3K5 | |
| SCHEMBL25319150 | 0.87 | PSEN1 (0.33) | MAP3K5IRAK4 | |
| SCHEMBL31351782 | 0.84 | MAP3K5 (0.38) | MAP3K5 | |
| SCHEMBL25320169 | 0.82 | LPL (0.38) | MAP3K5 | |
| SCHEMBL25319629 | 0.80 | MAP3K5 (0.41) | MAP3K5 | |
| SCHEMBL25317556 | 0.75 | MAP3K5 (0.44) | MAP3K5 | |
| SCHEMBL23281872 | 0.74 | IRAK4 (0.38) | IRAK4 | |
| Formaldehyde SCHEMBL28994699 | 0.72 | MAP3K5 (0.49) | MAP3K5 | |
| SCHEMBL12100499 | 0.72 | IRAK4 (0.44) | IRAK4 | |
| SCHEMBL19194377 | 0.71 | LPL (0.41) | IRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4747244-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LTD (GB) | 2025-04-17 | — | — | US | disclosed |
| WO-2025017306-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| WO-2025017305-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | REDX PHARMA LIMITED (GB) | 2025-01-23 | — | — | WO | disclosed |
| EP-4466071-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | Redx Pharma Limited (GB) | 2024-11-27 | — | — | EP | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
| WO-2023139379-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE (ROCK) | REDX PHARMA PLC (GB) | 2023-07-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250122173-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | ROCK1, ROCK2, RHOA | MAP3K5 84/4885IRAK4 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.